Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 5mg/mL (50mg/10mL) single-dose ampule
Acquired Methemoglobinemia
If methemoglobin level remains >30% or if clinical symptoms persist, repeat dose up to 1 mg/kg 1 hr after the first dose
Ifosfamide-induced Encephalopathy (Off-Label)
Prevention: 50 mg IVq6-8hr
Treatment: 50 mg once or q4-8hr until symptoms resolve
Dosing Considerations
Methemoglobinemia indication is approved under accelerated approval
Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials
Dosage Forms & Strengths
injectable solution
- 5mg/mL (50mg/10mL) single-dose ampule
Acquired Methemoglobinemia
If methemoglobin level remains >30% or if clinical symptoms persist, repeat dose up to 1 mg/kg 1 hr after the first dose
Dosing Considerations
Methemoglobinemia indication is approved under accelerated approval
Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
Pain in extremity (84%)
Chromaturia (74%)
Dysgeusia (20%)
Feeling hot (17%)
Dizziness (16%)
Hyperhidrosis (13%)
Nausea (13%)
Skin discoloration (13%)
1-10%
Headache (10%)
Musculoskeletal pain (9%)
Paresthesia oral (9%)
Paresthesia (9%)
Infusion site pain (6%)
Feeling cold (6%)
Pallor (5%)
Contact dermatitis (5%)
Syncope (4%)
Pruritus (4%)
Anxiety (4%)
Decreased appetite (4%)
Chest discomfort (4%)
Back pain (2%)
Cold sweat (2%)
Dizziness postural (2%)
Muscle spasms (2%)
Presyncope (2%)
Arthralgia (2%)
Chills (2%)
Diarrhea (2%)
Discomfort (2%)
Dyspnea (2%)
Erythema (2%)
Hypoesthesia oral (2%)
Infusion site discomfort (2%)
Limb discomfort (2%)
Oral discomfort (2%)
Catheter site pain (2%)
Ecchymosis (2%)
Warnings
Black Box Warnings
May cause serious or fatal serotonergic syndrome when coadministered with serotonergic drugs
Avoid coadministration with SSRIs, SNRIs, and MAOIs
Contraindications
Severe hypersensitivity reactions to methylene blue or any other thiazine dye
Patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of hemolytic anemia
Cautions
Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, bronchospasm) reported; monitor vital signs and ECG during treatment; if severe hypersensitivity occurs, discontinue drug and initiate supportive treatment (see Administration and Contraindications)
Methemoglobinemia may not resolve or may rebound after response to treatment due to aryl amines (eg, aniline, sulfa drugs [dapsone]); monitor response to therapy with through resolution of methemoglobinemia
Patients with G6PD deficiency may not reduce methylene blue to its active form in vivo and thereby be ineffective (see Contraindications)
Hemolysis can occur during treatment of methemoglobinemia with methylene blue and anemia may occur; hemolytic anemia may not be apparent until ≥1 day after
The presence of methylene blue in the blood may result in an underestimation of the oxygen saturation reading by pulse oximetry
A fall in the Bispectral Index (BIS) has been reported following administration of methylene blue class products; if methylene blue is administered during surgery, alternative methods for assessing the depth of anesthesia should be employed
May cause confusion, dizziness and disturbances in vision; patients should refrain from driving or engaging in hazardous occupations or activities
Methylene blue is a blue dye which passes freely into the urine and may interfere with the interpretation of any urine test which relies on a blue indicator (eg, dipstick test for leucocyte esterase)
Methylene blue is extensively metabolized in the liver; monitor patients with any hepatic impairment for toxicities and potential drug interactions for an extended period of time following treatment
Approximately 40% of methylene blue is excreted by the kidneys; patients with any renal impairment should be monitored for toxicities and potential drug interactions for an extended period of time following treatment
Serotonin syndrome
- Avoid coadministration with serotonergic psychiatric drugs (eg, SSRIs, SNRIs, TCAs, MAOIs) due to increased risk of serotonin syndrome, unless indicated for life-threatening conditions or when urgent treatment is required such as emergency treatment of methemoglobinemia, ifosfamide-induced encephalopathy, or cyanide poisoning; methylene blue may increase serotonin CNS levels by MAO-A inhibition
- If methylene blue must be administered to a patient currently taking a serotonergic drug, stop serotonergic drug immediately and monitor for CNS toxicity; serotonergic therapy may be resumed 24 hours after the last dose of methylene blue, or after 2 weeks of monitoring (5 weeks if fluoxetine was taken), whichever comes first
- If possible, discontinue serotonergic psychiatric medication at least 2 weeks in advance of methylene blue treatment; fluoxetine, should be stopped at least 5 weeks in advance due to longer half-life
- Also see Black Box Warnings
Pregnancy & Lactation
Pregnancy
May cause fetal harm when administered to a pregnant woman
Intra-amniotic injection of pregnant women with a methylene blue class product during the second trimester was associated with neonatal intestinal atresia and fetal death
Lactation
There is no information regarding the presence of methylene blue in human milk, the effects on the breastfed infant, or the effects on milk production
Because of the potential for serious adverse reactions, including genotoxicity discontinue breastfeeding during and for up to 8 days after treatment
Pregnancy Categories
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Mechanism of Action
Methylene blue is a water soluble thiazine dye that promotes a nonenyzmatic redox conversion of metHb to hemoglobin
In situ, methylene blue is first converted to leucomethylene blue (LMB) via NADPH reductase; it is the LMB molecule which then reduces the ferric iron of metHb to the ferrous state of normal hemoglobin
It also combines with cyanide to form cyanmethemoglobin, which prevents the interference of cyanide with the cytochrome system
Absorption
Peak plasma concentration: 2,917 ng/mL
AUC: 13,977 ng·hr/mL
Distribution
Protein bound: 94%
Vd: 255 L
Metabolism
Metabolized by CYPs 1A2, 2C19 and 2D6 in vitro; however, the predominant in vitro pathway appears to be UGT-mediated conjugation by multiple UGT enzymes, including UGT1A4 and UGT1A9
Elimination
Half-life: 24 hr
Excretion: 40% unchanged in urine
Administration
IV Incompatibilities
0.9% NaCl (reduces methylene blue solubility)
Incompatible with caustic alkalis, iodides, dichromates, and oxidizing or reducing substances
IV Preparation
Solution is hypotonic and may be diluted before use in a solution of 50 mL D5W to avoid local pain, particularly in the pediatric population
Use the diluted solution immediately after preparation
Do not mix with 0.9% NaCl, because it has been demonstrated that chloride reduces the solubility of methylene blue
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit
IV Administration
Ensure patent venous access prior to administration
For IV use only, do not administer SC or IM
Administer IV slowly over 5-30 minutes
If the methemoglobin level remains >30% or if clinical signs and symptoms persist, a repeat dose of 1 mg/kg may be given 1 hr after the first dose
If methemoglobinemia does not resolve after 2 doses, consider initiating alternative interventions for treatment of methemoglobinemia
Monitor vital signs, ECG, and methemoglobin levels during treatment and through resolution of methemoglobinemia
Storage
Store at 20-25°C (68-77°F)
Do not refrigerate or freeze
Keep ampule in original container to protect from light
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
